Navigation Links
Stem Cell Treatments for First Responders in the News
Date:8/25/2011

ed over 20,000 cell products, and delivered over 6,000 products to be transplanted in patients."

Dr. Smith added, "We are working to align ourselves closely with leaders in the nuclear industry, our military services, and first responders, such as police and firemen, but this is a service that we offer to everyone. One day, storing your cells will be as typical as storing blood. As NeoStem works to deliver new cell therapeutics to meet unmet medical needs such as acute myocardial infarctions (AMI), we believe these new uses will drive interest to make cell collection and storage commonplace for all."

About NeoStem, Inc.NeoStem is engaged in the development and manufacturing of cell-based therapies in the U.S. Its January, 2011 acquisition of Progenitor Cell Therapy, and its July 13, 2011 agreement to acquire Amorcyte, Inc. (which is expected to close in the fourth quarter subject to shareholder approval) position NeoStem to achieve its mission of capturing the paradigm shift to cell therapy.

PCT not only gives NeoStem access to a world class contract manufacturing cell therapy company, but provides NeoStem a platform and expertise around the evaluation, development and regulatory requirements necessary to develop autologous, allogeneic, immunomodulatory and vaccine-based therapeutics.

NeoStem also holds the worldwide exclusive license to VSEL™ Technology, which uses very small embryonic-like stem cells, shown to have several physical characteristics that are generally found in embryonic stem cells, and is pursuing the licensing of other technologies for therapeutic use. NeoStem owns 80% of Athelos Corporation, a company developing a T-cell therapeutic with potential in a range of auto-immune conditions such as graft versus host disease, asthma and diabetes. NeoStem's acquisition of Amorcyte, once the transaction is completed, will give the Company a Phase II asset for the treatment of acute myocardial infarctions and a Phase I a
'/>"/>

SOURCE NeoStem, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Presbyterian Cancer Center to Offer Cancer Patients High-End VMAT Treatments With the Installation of Elekta Infinity
2. CyberKnife System Achieves 38 Percent Growth in Extracranial Treatments During Fiscal Year 2008
3. Bradmer sponsors physician panel to raise awareness of brain cancer treatments
4. ZhenSpa.com provides Spa Enthusiasts Affordable Alternatives for Expensive Spa Treatments
5. Pioneering Cancer Center Introduces Advanced Varian RapidArc(TM) Treatments for Cancer Patients in Central Germany
6. Mylans Matrix Selected by the Clinton HIV/AIDS Initiative and UNITAID as the Primary Supplier of Five Second-Line and Seven Pediatric HIV/AIDS Treatments
7. New MedPredict Report Reveals Top Alzheimers Experts Insights on Diagnostics and Treatments in Development Pipeline
8. Morphotek(R), Inc. Announces a Research Collaboration Agreement with Synageva BioPharma Corporation to Develop Potential Treatments for Cancer and Infectious Disease
9. NeoStem Featured on CBS2 News; Success of Licensed Stem Cell Treatments Shown for Arthritis and Orthopedic Problems; Procedure to be Used by NeoStem Affiliate in China
10. Omnio Healer Selects Eden Biodesign for cGMP Production of its Candidate Wound Healing and Anti-Infection Treatments
11. Fast Forward, LLC and Amplimmune, Inc. Join Forces to Speed New Treatments to People with MS**
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... , July 28, 2015 Tauriga Sciences, Inc. ... life sciences company, today announced that its stockholders approved ... common stock of the Company from 1,000,000,000 to 2,500,000,000 ... 27, 2015 at the Law Offices of Nixon Peabody ... Special Meeting, there were 480,655,929 shares of common stock ...
(Date:7/28/2015)... /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS ) ... to German life sciences entrepreneurs with a proven ... biotechnology (collectively, the "Optionee"), an option to license ... technology (the "Technology"), including AEZS-120, the most advanced ... to enter a Phase 1 clinical trial. This ...
(Date:7/27/2015)... Tenn. , July 27, 2015  Capella ... care services and one of the largest for-profit ... its parent company and sole stockholder, Capella Holdings, ... Properties Trust, Inc. ("MPT") (NYSE: MPW ) ... The transaction is expected to be finalized during ...
(Date:7/27/2015)... 27, 2015   Inocucor Technologies Inc ., ... accelerators for farmers, has received a notice of ... for its patent application to protect Inocucor consortia ... and enhance yields on farms and in greenhouses. ... live IN-M1 microbial consortium and its fermentation byproducts, ...
Breaking Biology Technology:Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock 2Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock 3Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 2Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 3Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 2Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 3Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 4Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 5Inocucor Technologies Receives Groundbreaking U.S. Patent for Proprietary Biological Processes that Stimulate Plant Growth 2Inocucor Technologies Receives Groundbreaking U.S. Patent for Proprietary Biological Processes that Stimulate Plant Growth 3
... Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ... present a corporate overview of the Company at BioFinance ... The conference will be held at the Toronto Marriott ... the leading investor conference in Canada for the life ...
... Cadence Pharmaceuticals, Inc. (Nasdaq: CADX ) ... investigational product candidate, Acetavance(TM) (intravenous acetaminophen), will be presented ... Medicine (ASRA) 34th Annual Regional Anesthesia Meeting in Phoenix, ... of Hospital Medicine (SHM) Annual Meeting in Chicago, Illinois ...
... skin cells to combat aging and help support healing , ... ... Histogen Aesthetics , a division of Histogen focused on providing unique, ... the launch of the ReGenica™ Rejuvenation System for anti-aging and post-resurfacing. ...
Cached Biology Technology:Media Advisory - Oncolytics Biotech(R) Inc. to Present at BioFinance 2009 2Cadence Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences 2Histogen Aesthetics Launches ReGenica Rejuvenation System 2Histogen Aesthetics Launches ReGenica Rejuvenation System 3Histogen Aesthetics Launches ReGenica Rejuvenation System 4
(Date:7/9/2015)... , July 9, 2015  Synaptics Inc. (NASDAQ: SYNA ... today that it will report financial results for the ... 30, 2015 after the close of market. The company ... investors at 2:00 p.m. PT (5:00 p.m. ET), during ... To participate on the live call, analysts and investors ...
(Date:7/9/2015)... 9, 2015  Synaptics Inc. (NASDAQ: ... interface solutions, today announced a new Match-in-Sensor™ ... hardware encapsulated fingerprint sensor and matching solution. ... literally off the grid, isolating fingerprint image ... the fingerprint sensor to provide ultimate protection ...
(Date:7/8/2015)... , July 8, 2015  Trovagene, Inc. (NASDAQ: ... diagnostics, today announced the launch of a study ... Precision Cancer Monitoring℠ (PCM) technology for predicting response ... or a combination of the novel immunotherapy agents ... a PD-1 inhibitor. The 50-patient study will be ...
Breaking Biology News(10 mins):Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4
... (Land-use intensity and Ecological Engineering Assessment ... based production systems) is organizing a conference, entitled ... which will be held in Banaue, The Philippines ... 21 research institutions from Germany, Vietnam, The Philippines, ...
... Germany: The first report of the diagnostic use of the ... analysed, shows that it can give good results at low cost, ... of the European Society of Human Genetics today (Monday). ... around 20% of 100 cases of patients with intellectual disability (ID) ...
... Nature Medicine shows that boosting a protein ... from otherwise fatal radiation poisoning. Scientists in the ... June 24 say their findings open the potential ... or environmental exposures such as in a nuclear ...
Cached Biology News:Exome sequencing gives cheaper, faster diagnosis in heterogeneous disease 2Exome sequencing gives cheaper, faster diagnosis in heterogeneous disease 3Boosting blood system protein complex protects against radiation toxicity 2Boosting blood system protein complex protects against radiation toxicity 3
Topoisomerase I, isolated from wheat germ, is an enzyme capable of removing negative supercoils from covalently closed circular DNA (1)....
The Spheroplast Kit contains qualified reagents for the preparation of yeast spheroplasts. The reagents have been optimized for use with Pichia pastoris and are guaranteed to generate 70% spheroplast...
The Proteome Profiler Human Phospho-MAPK Array Kit contains 4 membranes - each spotted in duplicate with 23 different MAPK antibodies....
Mycoplasma tested...
Biology Products: